Skip to main content
. 2020 Apr 23;4(8):1656–1669. doi: 10.1182/bloodadvances.2019001043

Figure 2.

Figure 2.

PK of itacitinib on day 1 and day 7 stratified by concomitant CYP3A4 inhibitor use in relation to the concentration needed to inhibit IL-6- or TPO-induced STAT phosphorylation by 50%. Data are shown as mean ± standard error of the mean. *Only 6 patient samples were available for analysis at the first time point (baseline). IC50, half maximal inhibitory concentration; TPO, thrombopoietin.